Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8804007 | 0.80 | LMNA (0.43) | NPC1RAB9ALMNASMN1; SMN2ADORA3 | |
| SCHEMBL8802832 | 0.80 | ADORA3 (0.55) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL27454303 | 0.80 | LMNA (0.43) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL8999497 | 0.80 | RXFP1 (0.42) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL2213825 | 0.79 | ADORA3 (0.59) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL1219538 | 0.79 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL8807502 | 0.78 | CYP19A1 (0.44) | NPC1RAB9ASMN1; SMN2CYP19A1KDM4E | |
| SCHEMBL6531530 | 0.78 | CYP19A1 (0.62) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL31120321 | 0.78 | CYP19A1 (0.66) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL9852272 | 0.76 | ADORA3 (0.66) | NPC1RAB9AMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472166-B2 | Inhibition of mycobacterial type VII secretion | STICHTING VUMC (NL) | 2025-11-18 | — | — | US | disclosed |
| EP-4021898-B1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting Amsterdam UMC (NL) | 2024-05-29 | — | — | EP | disclosed |
| US-20220280487-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VU (NL) | 2022-09-08 | — | — | US | disclosed |
| EP-4021898-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting VUmc (NL) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021040519-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VUMC (NL) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021040519-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VUMC (NL) | 2021-03-04 | — | — | WO | disclosed |
| CN-1143962-A | Triazole compound and processes for preparation thereof | YUHAN CORP (KR) | 1997-02-26 | — | — | CN | disclosed |
| EP-0751943-A1 | TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 1997-01-08 | — | — | EP | disclosed |
| EP-0588007-B1 | Use of thiadiazoles as antifouling agent | WITCO GMBH (DE) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995025107-A1 | TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1995-09-21 | — | — | WO | disclosed |
| US-5332430-A | Use of thiadiazole compounds as an antifouling active ingredient | WITCO GMBH (DE) | 1994-07-26 | — | — | US | disclosed |
| EP-0588007-A1 | Use of thiadiazoles as antifouling agent | Witco GmbH (DE) | 1994-03-23 | — | — | EP | disclosed |
| US-4985450-A | TREATMENT OF GLAUCOMA | AVENTIS PHARMACEUTICALS INC. | 1991-01-15 | — | — | US | disclosed |
| US-4873239-A | GLAUCOMA TREATMENT | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0276822-A1 | Arylthiadiazolylsulfonamides and derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4758578-A | Arylthiadiazolylsulfonamides, pharmaceutical compositions and use | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472166-B2 | Inhibition of mycobacterial type VII secretion | CFTR, ABCB11, ABCC2 | NPC1 526/4885RAB9A 1228/4885MEN1 1427/4885 |
| US-20220280487-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | CFTR, ABCB11, ABCC2 | NPC1 526/4885RAB9A 1228/4885MEN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.